Anixa Biosciences, Inc. (ANIX)

$3.1

+0.05

(+1.64%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Anixa Biosciences, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 85.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 261.3%

Performance

  • $3.03
    $3.13
    $3.10
    downward going graph

    2.26%

    Downside

    Day's Volatility :3.19%

    Upside

    0.96%

    downward going graph
  • $2.75
    $5.13
    $3.10
    downward going graph

    11.29%

    Downside

    52 Weeks Volatility :46.39%

    Upside

    39.57%

    downward going graph

Returns

PeriodAnixa Biosciences, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-38.51%
-0.7%
0.0%
6 Months
-2.82%
7.7%
0.0%
1 Year
-36.99%
3.3%
-1.7%
3 Years
-23.65%
13.9%
-20.7%

Highlights

Market Capitalization
98.9M
Book Value
$0.78
Earnings Per Share (EPS)
-0.34
Wall Street Target Price
12.0
Profit Margin
0.0%
Operating Margin TTM
-5744.76%
Return On Assets TTM
-28.09%
Return On Equity TTM
-43.02%
Revenue TTM
210.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
127.5K
EBITDA
-13.1M
Diluted Eps TTM
-0.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.44
EPS Estimate Next Year
-0.45
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Anixa Biosciences, Inc.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 287.1%

Current $3.10
Target $12.00

Technicals Summary

Sell

Neutral

Buy

Anixa Biosciences, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Anixa Biosciences, Inc.
Anixa Biosciences, Inc.
-13.89%
-2.82%
-36.99%
-23.65%
-24.02%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Anixa Biosciences, Inc.
Anixa Biosciences, Inc.
NA
NA
NA
-0.44
-0.43
-0.28
NA
0.78
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Anixa Biosciences, Inc.
Anixa Biosciences, Inc.
Buy
$98.9M
-24.02%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • Vanguard Group Inc

    4.37%
  • UBS Group AG

    1.82%
  • Mission Wealth Management, LLC

    1.57%
  • Laird Norton Tyee Trust Co

    1.16%
  • Geode Capital Management, LLC

    0.98%
  • Long Focus Capital Management, LLC

    0.52%

Corporate Announcements

  • Anixa Biosciences, Inc. Earnings

    Anixa Biosciences, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues

Organization
Anixa Biosciences, Inc.
Employees
4
CEO
Dr. Amit Kumar Ph.D.
Industry
Electronic Technology

FAQs